Cyclerion Therapeutics (CYCN) Liabilities and Shareholders Equity (2019 - 2025)
Historic Liabilities and Shareholders Equity for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $10.4 million.
- Cyclerion Therapeutics' Liabilities and Shareholders Equity rose 1704.88% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.2 million, marking a year-over-year decrease of 1028.35%. This contributed to the annual value of $9.6 million for FY2024, which is 2840.59% down from last year.
- Per Cyclerion Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $10.4 million for Q3 2025, which was up 1704.88% from $9.4 million recorded in Q2 2025.
- In the past 5 years, Cyclerion Therapeutics' Liabilities and Shareholders Equity ranged from a high of $100.0 million in Q1 2021 and a low of $8.9 million during Q3 2024
- In the last 5 years, Cyclerion Therapeutics' Liabilities and Shareholders Equity had a median value of $13.4 million in 2023 and averaged $28.8 million.
- Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 7537.67% in 2023, then skyrocketed by 1704.88% in 2025.
- Quarter analysis of 5 years shows Cyclerion Therapeutics' Liabilities and Shareholders Equity stood at $59.3 million in 2021, then plummeted by 69.53% to $18.1 million in 2022, then fell by 26.02% to $13.4 million in 2023, then fell by 28.41% to $9.6 million in 2024, then rose by 8.77% to $10.4 million in 2025.
- Its Liabilities and Shareholders Equity was $10.4 million in Q3 2025, compared to $9.4 million in Q2 2025 and $9.8 million in Q1 2025.